JC03 Rec'd PCT/PTO 0 5 DEC 2001

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Francois HIRSCH et al.

Serial No. 09/856,796 (PCT/FR99/02897)

Box PCT

Attention: DO/EO

Filed September 7, 2001

NF-KB ACTIVATION INHIBITORS AND THEIR PHARMAEUTICAL USES

RESPONSE

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This responds to the Notification of Defective response mailed November 5, 2001.

The Notification of Defective Response asserts that the previously-filed sequence listing is non-compliant with 37 CFR 1.821-1.825 as indicated on a marked-up copy of the raw sequence listing said to be attached to the notification. However, no marked-up copy of the raw sequence listing was attached to the notification. Therefore, applicants have independently reviewed the sequence listing filed September 5, 2001, in an attempt to identify any defects therein which might have prompted issuance of the Notification of Defective Response on November 5, 2001. No defect has been detected in the sequence listing filed September 5, 2001. We observe that in the field 130, applicants' reference for this case is indicated as "USB98CNRN", whereas the correct attorney docket number is "USB 98 CNR NFK"; however, the HIRSCH et al. - S.N. 09/856,796

attorney docket is not a mandatory field, and therefore is not believed to be a basis for generating a Notification of Defective Response.

To the extent that the submission of September 5, 2001 was considered inadequately to direct entry into the present specification of the sequence listing, applicants hereby explicitly direct that the sequence listing filed September 5, 2001 be entered into the present specification.

In the event that the sequence listing filed September 5, 2001, became separated from the patent office file, a duplicate copy of the sequence listing in paper and disk formats is hereby submitted, together with a copy of the statement in support thereof as filed on September 5, 2001, and a copy of the associated postcard receipt.

Therefore, it is believed that the present paper established compliance with the sequence listing requirements. To the extent that any requirement is deemed to remain unsatisfied, it is respectfully requested that a fresh notification be issued identifying the perceived defect with specificity.

Respectfully submitted,
YOUNG & THOMPSON

ou (BAAD) //

Attorney for Applicants Registration No. 32,925

745 South 23rd Street Arlington, VA 22202 Telephone: 521-2297


December 5, 2001

THE STAMP UP THE PATENT OFFICE MAIL HEREON AUXNOWLEDGES THE RECEIPT OF THE BELOW-IDENTIFIED DOCUMENT ON THE DATE NEICATED BY SUCH STAMP.

	•		/	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
In re: S.N	Francois HIRSCH et	al.	CEP	0 2 5001 \$
	09/856,796	Exorp Box	SEQUENCE	TRAVEMANT
	STATEMENT TO SUPPORT	r FILING		
	ACCORDANCE WITH 37	C.F.R. §1	1.821-1.825	7 pgs.

total) also attached: 1 cc. of NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED? ELECTED OFFICE (DO/EO/US) and NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

bg



Date Mailed: 11/05/2001

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- · Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply
 with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason
 (s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended up to a maximum of six months.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

PAULETTE R KIDWELL

Telephone: (703) 305-3656

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/856,796	PCT/FR99/02897	USB 98 CNR NFK